Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Meeting ReportSymposium Article

Molecular and Physical Mechanisms of First-Pass Extraction

Stephen D. Hall, Kenneth E. Thummel, Paul B. Watkins, Kenneth S. Lown, Leslie Z. Benet, Mary F. Paine, Robert R. Mayo, D. Kim Turgeon, David G. Bailey, Robert J. Fontana and Steven A. Wrighton
Drug Metabolism and Disposition February 1999, 27 (2) 161-166;
Stephen D. Hall
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth E. Thummel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul B. Watkins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth S. Lown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslie Z. Benet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary F. Paine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert R. Mayo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Kim Turgeon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David G. Bailey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Fontana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Wrighton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

This is a report of a symposium held at the March 1997 meeting of the American Society for Pharmacology and Therapeutics in San Diego. Our understanding of the events that control first-pass drug elimination in humans has increased tremendously by two sequential discoveries. First, cytochrome P-450s 3A4 and 5 are expressed at high concentrations in both hepatocytes and upper intestinal enterocytes, and therefore limit the systemic availability of many drugs. Second, P-glycoprotein is expressed at the lumenal surface of the intestinal epithelium and therefore also acts to oppose the absorption of unchanged drug. The following discussion brings together our current understandings of these interrelated phenomena to aid a more complete picture of how they may contribute both qualitatively and quantitatively to first-pass elimination.

Footnotes

  • Send reprint requests to: Stephen D. Hall, Ph.D., Clinical Pharmacology, 320 OPW Wishard Hospital, 1001 West Tenth Street, Indianapolis, IN 46202. E-mail: sdhall{at}iupui.edu

  • ↵1 Conflict of Interest Statement: Dr. Watkins owns equity in Metabolic Solutions, Inc., (Merrimack, NH) which manufactures and sells the ERMBT kit and he is also Chairman of the Scientific Advisory Board of Avmax.

  • Supported by National Institutes of Health Grants GM38149-11 (P.B.W.), GM53095-01 (K.S.L.), and MO1 RR00042 (University of Michigan General Clinical Research Center), and Grant MA-11584 from the Medical Research Council of Canada.

  • Abbreviations used are::
    CYP
    cytochrome P-450
    ERMBT
    erythromycin breath test
    AUC
    area under the plasma concentration time curve
    Cmax
    maximum plasma concentration
    P-gp
    P-glycoprotein
    Vmax
    maximal rate of metabolism
    ka
    absorption rate constant
    kgm
    rate constant for gut wall metabolism
    • Received August 19, 1998.
    • Accepted September 1, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (2)
Drug Metabolism and Disposition
Vol. 27, Issue 2
1 Feb 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Molecular and Physical Mechanisms of First-Pass Extraction
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Meeting ReportSymposium Article

Molecular and Physical Mechanisms of First-Pass Extraction

Stephen D. Hall, Kenneth E. Thummel, Paul B. Watkins, Kenneth S. Lown, Leslie Z. Benet, Mary F. Paine, Robert R. Mayo, D. Kim Turgeon, David G. Bailey, Robert J. Fontana and Steven A. Wrighton
Drug Metabolism and Disposition February 1, 1999, 27 (2) 161-166;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Meeting ReportSymposium Article

Molecular and Physical Mechanisms of First-Pass Extraction

Stephen D. Hall, Kenneth E. Thummel, Paul B. Watkins, Kenneth S. Lown, Leslie Z. Benet, Mary F. Paine, Robert R. Mayo, D. Kim Turgeon, David G. Bailey, Robert J. Fontana and Steven A. Wrighton
Drug Metabolism and Disposition February 1, 1999, 27 (2) 161-166;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Role of Enterocyte CYP3A in the First-Pass Extraction of Midazolam (K.E.T., M.F.P.)
    • Assessing the Role of Intestinal CYP3A4 in Limiting Oral Delivery of Drugs: New Approaches (P.B.W., D.G.B., K.S.L., R.J.F.)
    • The Emerging Role of Intestinal P-Glycoprotein (MDR1) in Oral Drug Availability (K.S.L., R.R.M., D.K.T., P.B.W.)
    • Overlapping Substrate Specificities of CYP3A4 and P-Glycoprotein: Implications in Drug Delivery (L.Z.B.)
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Targeting Drug-Metabolizing Enzymes for Effective Chemoprevention and Chemotherapy
  • TRANSCRIPTIONAL SUPPRESSION OF CYTOCHROME P450 GENES BY ENDOGENOUS AND EXOGENOUS CHEMICALS
  • GLUCURONIDATION AND THE UDP-GLUCURONOSYLTRANSFERASES IN HEALTH AND DISEASE
Show more SYMPOSIUM ARTICLE

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics